Matt Sagan/X
Jun 22, 2025, 01:25
Matt Sagan: Cancer Vaccines and the future of immunotherapy
Matt Sagan, Founder, Managing Partner and CEO of MoD Partners and Executive Director of BioForum Accelerator, shared a post on X:
” ‘Cancer Vaccines and the future of immunotherapy’ super review at The Lancet is a great article (just had a chance to read it).
As its pay-per-view article I’m not allowed to make it public.
I will point out key lessons learned for everyone interested in the subject:
-
More effective cancer vaccines are being developed through having a deeper understanding of crucial cellular factors in tumor immunology;
-
CancerVaccines generally aim to deliver antigens to dendritic cells, which are the most potent activators of antigen-specific Tcells. Once the T cells are activated, they will expand, mobilise, and kill cancer cells systemically;
-
Newer vaccines are being designed to improve the expansion of cancer-killing Tcells and overcome the tumoural resistance mechanisms;
-
Cancer Vaccines are an important modality in the immunotherapy arsenal by enhancing the strength and breadth of anti-tumour T-cell responses, prolonging remissions in the adjuvant setting, and inducing systemic regressions of metastatic solid tumors and hematological cancers;
-
Cancer Vaccines will undoubtedly become more effective in the coming decade as we further establish the biological understanding and technical capabilities for total programmable control of anti-tumor immune responses.”
More posts featuring Matt Sagan on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 3, 2025, 11:29
Jul 3, 2025, 10:55
Jul 3, 2025, 10:25
Jul 3, 2025, 10:24
Jul 3, 2025, 10:16
Jul 3, 2025, 10:15